Clinical Trials Logo
  1. Home
  2. Dumping Syndrome
  3. NCT04522193

Dumping Syndrome and Esophageal Atresia — DUMTORING  

Dumping Syndrome Clinical Trial

Official title:
Physiopathology of Dumping Syndrome in Esophageal Atresia

Clinical Trial Summary

Dumping syndrome (DS) is frequent in oesophageal atresia (29%). In causing hypoglycaemia, it can be dangerous for neonates. Mechanisms of DS are actually partialy understood. This is also an affection difficult to diagnose, because it only occurs after meals and can be inconstantly present. To date, their is only symptomatic treatment for DS. This study aims to understand its pathological mechanisms so as to better treat it and avoid its consequences. Oesophageal atresia patients enrolled in this study will benefit from a continuous glycemic monitoring, a continuous cardiac monitoring, and an a gastric emptying scintigraphy at the age of 3 months

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04522193
Study type Interventional
Source University Hospital, Lille
Contact Madelaine AUMAR, MD
Phone 0320445962
Email madeleine.aumar@chru-lille.fr
Status Not yet recruiting
Phase N/A
Start date November 2021
Completion date November 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05759689 - Fat Supplementation on Dumping Syndrome Related Symptoms After Gastric Surgery N/A
Recruiting NCT04028193 - Fat Supplementation on Dumping Syndrome Associated Symptoms N/A
Recruiting NCT00543179 - Treatment of the Dumping Syndrome With Lanreotide Autogel® Phase 4
Completed NCT02891330 - Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity N/A
Completed NCT02525705 - Dumping Syndrome After Operation of Esophageal Atresia Type III N/A
Completed NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT03734627 - Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
Terminated NCT02836353 - Metabolic Consequences of Gastrointestinal Surgery N/A
Completed NCT05057819 - Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass Phase 4
Completed NCT02971631 - Gastrectomy, Eating Behaviour and GLP-1 N/A
Completed NCT01923649 - SOMATULINE Autogel 90 mg IN DUMPING SYNDROME Phase 2